Analysts Issue Forecasts for Kura Oncology FY2030 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Brookline Capital Management issued their FY2030 earnings per share estimates for shares of Kura Oncology in a research report issued on Monday, January 5th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $26.89 for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other analysts have also issued reports on KURA. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Friday, November 14th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. JMP Securities reissued a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a research report on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Wednesday, October 8th. Finally, Barclays reiterated an “overweight” rating and issued a $28.00 price objective (up previously from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Kura Oncology Trading Up 4.5%

Shares of KURA stock opened at $9.97 on Tuesday. The firm has a market capitalization of $867.59 million, a P/E ratio of -4.02 and a beta of 0.25. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $12.49. The firm’s fifty day simple moving average is $10.75 and its 200 day simple moving average is $8.74. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 15,485 shares of Kura Oncology stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $173,122.30. Following the sale, the insider directly owned 225,454 shares of the company’s stock, valued at approximately $2,520,575.72. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian T. Powl sold 8,887 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $11.18, for a total value of $99,356.66. Following the completion of the sale, the insider owned 139,689 shares in the company, valued at approximately $1,561,723.02. This represents a 5.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 68,343 shares of company stock valued at $730,858 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its position in Kura Oncology by 0.9% in the third quarter. Rhumbline Advisers now owns 119,935 shares of the company’s stock valued at $1,061,000 after acquiring an additional 1,039 shares during the period. Profund Advisors LLC lifted its holdings in shares of Kura Oncology by 11.1% during the third quarter. Profund Advisors LLC now owns 24,835 shares of the company’s stock valued at $220,000 after acquiring an additional 2,478 shares during the period. Arizona State Retirement System increased its position in shares of Kura Oncology by 15.8% during the 3rd quarter. Arizona State Retirement System now owns 20,481 shares of the company’s stock worth $181,000 after purchasing an additional 2,802 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Kura Oncology by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock worth $175,000 after purchasing an additional 2,976 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the last quarter.

Key Headlines Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: Brookline published a long‑range bullish projection, initiating/issuing a FY2030 EPS forecast of $26.89, which signals an analyst view of substantial long‑term upside if Kura’s pipeline and commercialization progress succeed. This optimistic long‑term target can support risk‑on buying despite nearer‑term headwinds.
• Neutral Sentiment: Brookline trimmed its FY2029 estimate slightly to $11.72 from $12.08 — a modest downgrade to a distant year that is less likely to move the stock materially on its own.
• Negative Sentiment: Brookline cut near‑ and medium‑term EPS forecasts materially: Q4 2025 to ($0.61) from ($0.48) previously, FY2025 to ($2.87), FY2026 to ($1.41) (worse than prior ($0.42)), FY2027 down sharply to $0.32 (from $2.94) and FY2028 to $3.62 (from $5.78). Those downward revisions reduce near‑term profitability expectations and can pressure the stock as they lower the short‑to‑medium‑term earnings trajectory and increase execution risk.
• Negative Sentiment: Management change: former Kura CMO Stephen Dale has joined Syncromune, which may raise questions about clinical/regulatory leadership continuity at Kura until a replacement is named. Article Title

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.